^
    Back
    Association details:
    Biomarker:High IFNG gene signature
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2023
    Title:

    Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

    Published date:
    05/25/2023
    Excerpt:
    ...efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma...Higher IFNγ-sig, TMB, and % CD8+ T cells, and lower CRP levels were associated with longer RFS with NIVO treatment.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9504
    Trial ID:
    CheckMate76K